General Information of Drug (ID: DMIIZ4R)

Drug Name
MK-5475 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMIIZ4R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [3]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [4]
Sodium nitroprusside DMGA9X0 Hypertension BA00-BA04 Approved [5]
IW-1973 DMK2T7J Heart failure BD10-BD13 Phase 2 [6]
CTI-1601 DMM4JMB Friedreich's ataxia 8A03.10 Phase 2 [7]
Runcaciguat DMCFTTN Chronic kidney disease GB61 Phase 2 [8]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [9]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [10]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Stimulator [2]

References

1 ClinicalTrials.gov (NCT05612035) A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
2 Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.
3 Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
4 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
5 Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
8 Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
9 First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
10 Clinical pipeline report, company report or official report of Cyclerion Therapeutics